Shares of Neos Therapeutics, Inc. (NASDAQ:NEOS) have been given an average rating of “Buy” by the eight ratings firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and five have issued a buy recommendation on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $15.25.
NEOS has been the subject of several analyst reports. Zacks Investment Research downgraded shares of Neos Therapeutics from a “buy” rating to a “sell” rating in a research note on Thursday, October 19th. Cantor Fitzgerald reissued a “buy” rating and issued a $20.00 price objective on shares of Neos Therapeutics in a research note on Tuesday, September 26th. Cowen reissued a “buy” rating on shares of Neos Therapeutics in a research note on Thursday, October 26th. Wells Fargo & Company set a $14.00 price objective on shares of Neos Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, October 18th. Finally, ValuEngine raised shares of Neos Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 12th.
Neos Therapeutics (NEOS) opened at $9.98 on Friday. The company has a current ratio of 2.42, a quick ratio of 2.14 and a debt-to-equity ratio of 4.01. Neos Therapeutics has a 1-year low of $4.85 and a 1-year high of $13.15.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its position in shares of Neos Therapeutics by 25.7% during the second quarter. Vanguard Group Inc. now owns 740,160 shares of the company’s stock worth $5,403,000 after acquiring an additional 151,166 shares during the period. Cortina Asset Management LLC purchased a new position in shares of Neos Therapeutics during the third quarter worth approximately $5,312,000. Stonepine Capital Management LLC purchased a new position in shares of Neos Therapeutics during the second quarter worth approximately $4,125,000. State Street Corp increased its position in shares of Neos Therapeutics by 29.6% during the second quarter. State Street Corp now owns 316,855 shares of the company’s stock worth $2,312,000 after acquiring an additional 72,395 shares during the period. Finally, Columbus Circle Investors increased its position in shares of Neos Therapeutics by 156.2% during the second quarter. Columbus Circle Investors now owns 272,934 shares of the company’s stock worth $1,992,000 after acquiring an additional 166,414 shares during the period. 45.93% of the stock is owned by institutional investors and hedge funds.
Neos Therapeutics Company Profile
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.